Psyence Biomedical Ltd. Issues Press Release
Ticker: PBMWW · Form: 6-K · Filed: Sep 13, 2024 · CIK: 1985062
| Field | Detail |
|---|---|
| Company | Psyence Biomedical LTD. (PBMWW) |
| Form Type | 6-K |
| Filed Date | Sep 13, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: press-release, foreign-private-issuer
TL;DR
Psyence Biomedical Ltd. dropped a press release on 9/13/24.
AI Summary
On September 13, 2024, Psyence Biomedical Ltd. announced the issuance of a press release. The company, incorporated in Ontario, Canada, is a pharmaceutical preparations company located in Toronto.
Why It Matters
This filing indicates that Psyence Biomedical Ltd. has made a public announcement, which could contain material information for investors.
Risk Assessment
Risk Level: low — This filing is a routine report of a press release and does not contain significant new financial or operational information.
Key Players & Entities
- Psyence Biomedical Ltd. (company) — Registrant
- September 13, 2024 (date) — Date of press release issuance
- Toronto, Ontario (location) — Company headquarters
FAQ
What is the primary business of Psyence Biomedical Ltd.?
Psyence Biomedical Ltd. is in the Pharmaceutical Preparations industry, SIC code 2834.
Where is Psyence Biomedical Ltd. headquartered?
The company's business and mailing address is 121 Richmond Street West Penthouse Suite 1300, Toronto, Ontario M5H 2K1.
What form is Psyence Biomedical Ltd. filing?
Psyence Biomedical Ltd. is filing a Form 6-K, which is a Report of Foreign Private Issuer.
When was this Form 6-K filed?
This Form 6-K was filed on September 13, 2024.
Does Psyence Biomedical Ltd. file annual reports under Form 20-F or 40-F?
Psyence Biomedical Ltd. indicates it files annual reports under cover of Form 20-F.
Filing Stats: 267 words · 1 min read · ~1 pages · Grade level 10.8 · Accepted 2024-09-13 17:00:30
Filing Documents
- tm2424049d1_6k.htm (6-K) — 12KB
- tm2424049d1_ex99-1.htm (EX-99.1) — 12KB
- tm2424049d1_ex99-1img001.jpg (GRAPHIC) — 3KB
- 0001104659-24-099851.txt ( ) — 28KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001-41937 Psyence Biomedical Ltd. (Translation of registrant’s name into English) 121 Richmond Street West Penthouse Suite 1300 Toronto, Ontario M5H 2K1 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F X Form 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): On September 13, 2024, Psyence Biomedical Ltd., a corporation organized under the laws of Ontario, Canada (the “ Company ”), issued a press release announcing that, on September 12, 2024, the Company received a letter from the listing qualifications department staff of The Nasdaq Stock Market (“ Nasdaq ”). A copy of the press release is furnished hereto as Exhibit 99.1. The contents of such press release are incorporated by reference herein. EXHIBIT INDEX Exhibit No. Description 99.1 Press Release SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Dated: September 13, 2024 Psyence Biomedical Ltd. By: /s/ Dr. Neil Maresky Name: Dr. Neil Maresky Title: Chief Executive Officer and Director